Skip to main content
SpringerLink
Log in

Cardiovascular toxicity with highly active antiretroviral therapy

Review of clinical studies

  • Reviews
  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Highly active antiretroviral therapy (HAART) has dramatically improved the life expectancy of patients with human immunodeficiency virus (HIV). Specific toxicities cited for HAART include elevations in serum levels of total cholesterol and triglycerides, reduction in high-density lipoprotein cholesterol, alterations in the distribution of body fat, increases in insulin resistance, and diabetes, which are major risk factors for cardiovascular disease (CVD). The majority of the studies examining the incidence of CV events demonstrated an increase in CV event rate with HAART in the HIV-infected population. Overall, the CVD risk appears to be greater in the HIV-infected population than in the general population, and the increased CV risk is associated with HAART, particularly with protease inhibitor use. Despite the relative risk (RR) for CVD being significantly high (the hazard ratio for myocardial infarction ranging between 1.3 and 7.1), the absolute risk for CVD remains low, with the CV event rates ranging between one and seven events per 1000 person-years. Although there is general consensus that the benefits of HAART far outweigh toxicity-related risks of the treatment with HAART, prolonged survival among HIV-infected patients will likely support the use of different antiretroviral regiments with potentially less CV toxicity in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., et al. (199). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853–860.

    Article  Google Scholar 

  2. (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421.

  3. Holmberg, S.D., Moorman, A.C., Williamson, J.M., Tong, T.C., Ward, D.J., Wood, K.C., et al. (2002). Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748.

    Article  PubMed  CAS  Google Scholar 

  4. Henry, K., Melroe, H., Huebsch, J., Hermundson, J., Levine, C., Swensen, L., et al. (1998). Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328.

    Article  PubMed  CAS  Google Scholar 

  5. Friis-Moller, N., Sabin, C.A., Weber, R., d’Arminio, M.A., El Sadr, W.M., Reiss, P., et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349:1993–2003.

    Article  PubMed  Google Scholar 

  6. Klein, D., Hurley, L.B., Quesenberry, C.P. Jr. and Sidney, S. (2002). Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30:471–477.

    PubMed  CAS  Google Scholar 

  7. Mulligan, K., Grunfeld, C., Tai, V.W., Algren, H., Pang, M., Chernoff, D.N., et al. (2000). Hyperlipiedemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23:35–43.

    PubMed  CAS  Google Scholar 

  8. Mooser, V. and Carr, A. (2001). Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr. Opin. Lipidol. 12:313–319.

    Article  PubMed  CAS  Google Scholar 

  9. Noor, M.A., Senevirantne, T., Aweeka, F.T., Lo, J.C., Schwarz, J.M., Mulligan, K., et al. (2002). Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-F8.

    Article  PubMed  Google Scholar 

  10. Vigouroux, C., Gharakhanian, S., Salhi, Y., Nguyen, T.H., Adda, N., Rozenbaum, W., et al. (1999). Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:383–392.

    PubMed  CAS  Google Scholar 

  11. Vigouroux, C., Gharakhanian, S., Salhi, Y., Nguyen, T.H., Chevenne, D., Capeau, J., et al. (1999). Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 25:225–232.

    PubMed  CAS  Google Scholar 

  12. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58.

    Article  PubMed  CAS  Google Scholar 

  13. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G.R., Chisholm, D.J., and Cooper, D.A. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093–2099.

    Article  PubMed  CAS  Google Scholar 

  14. Haubrich, R., Miller, C., Gathe, J., Pearce, D., Dretler, R., and Petersen, C. The effect of NFV versus EFV on fasting lipid levels: interim analysis from a prospective randomized study in treatment naive patients (AG1127). Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA. Abstract H-1914.

  15. Van der Valk, M., and Reiss, P. (2003). Lipid profiles associated with antiretroviral drug choices. Curr. Opin. Infect. Dis. 16:19–23.

    PubMed  Google Scholar 

  16. David, M.H., Hornung, R., and Fichtenbaum, C.J. (2002). Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin. Infect. Dis. 34:98–102.

    Article  PubMed  Google Scholar 

  17. Grunfeld, C., Kotler, D.P., Hamadeh, R., Tierney, A., Wang, J., and Pierson, R.N. (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86:27–31.

    Article  PubMed  CAS  Google Scholar 

  18. Constans, J., Pellegrin, J.L., Peuchant, E., Dumon, M.F., Pellegrin, I., Sergeant, C., et al. (1994). Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur. J. Clin. Invest. 24:416–420.

    Article  PubMed  CAS  Google Scholar 

  19. Matthews, G.V., Moyle, G.J., Mandalia, S., Bower, M., Nelson, M., and Gazzard, B.G. (2000). Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J. Acquir. Immune Defic. Syndr. 24:310–315.

    PubMed  CAS  Google Scholar 

  20. Wilson, P.W., D’Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., and Kannel, W.B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847.

    PubMed  CAS  Google Scholar 

  21. Assmann, G., Cullen, P., and Schulte, H. (2002). Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310–315.

    Article  PubMed  Google Scholar 

  22. Saves, M., Chene, G., Ducimetiere, P., Leport, C., Le Moal, G., Amouyel, P., et al. (2003). Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin. Infect. Dis. 37:292–298.

    Article  PubMed  Google Scholar 

  23. Wall, J.L., David, M., and Fichtenbaum C.J. The risk of ischemic cardiovascular disease is significant in persons with HIV infection. Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle. Abstract 695.

  24. Hadigan, C., Meigs, J.B., Wilson, P.W., D’Agostino, R.B., Davis, B., Basgoz, N., et al. (2003). Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin. Infect. Dis. 36:909–916.

    Article  PubMed  Google Scholar 

  25. Justman, J.E., Benning, L., Danoff, A., Minkoff, H., Levine, A., Greenblatt, R.M., et al. (2003). Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J. Acquir. Immune Defic. Syndr. 32:298–302.

    Article  PubMed  CAS  Google Scholar 

  26. El Sadr, W., Neaton, J., Neuhaus, J., and Gordin, F. Comparison of risk factors for coronary heart disease among men and women enrolled in the SMART study (CPCRA 065). Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 745.

  27. Talwani, R., Falusi, O.M., Mendes de Leon, C.F., Nerad, J.L., Rich, S., Proia, L.A., et al. (2002). Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 30:191–195.

    PubMed  Google Scholar 

  28. Seminari, E., Pan, A., Voltini, G., Carnevale, G., Maserati, R., Minoli, L., et al. (2002). Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162:433–438.

    Article  PubMed  CAS  Google Scholar 

  29. Maggi, P., Serio, G., Epifani, G., Fiorentino, G., Saracino, A., Fico, C., et al. (2000). Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14:F123-F128.

    Article  PubMed  CAS  Google Scholar 

  30. Chironi, G., Escaut, L., Gariepy, J., Cogny, A., Teicher, E., Monsuez, J.J., et al. (2003). Brief report: caritid intima-media thickness in heavily pretreated HIV-infected patients J. Acquir. Immune Defic. Syndr. 32:490–493.

    Article  PubMed  Google Scholar 

  31. Depairon, M., Chessex, S., Sudre, P., Rodondi, N., Doser, N., Chave, J.P., et al. (2001). Premature atherosclerosis in HIV-infected individuals—focus on protease inhibitor therapy. AIDS 15:329–334.

    Article  PubMed  CAS  Google Scholar 

  32. Mercie, P., Thiebaut, R., Lavignolle, V., Pellegrin, J.L., Yvorra-Vives, M.C., Morlat, P., et al. (2002). Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann. Med. 34:55–63.

    Article  PubMed  Google Scholar 

  33. Hsue, P., Lo, J., Franklin, A., Bolger, A.F., Deeks, S.G., and Waters, D.D. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunologic risk factors. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 139Lb.

  34. Meng, Q., Lima, J.A., Lai, H., Vlahov, D., Celentano, D.D., Strathdee, S.A., et al. (2002). Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am. Heart J. 144:642–648.

    PubMed  Google Scholar 

  35. Taubald, A. Coronary Artery Calcium (CAC) scores with PI treatment in HIV+patients. XIV International AIDS Conference; July 7–12, 2002; Barcelona.

  36. Lai, S., Lai, H., Meng, Q., Tong, W., Vlahov, D., Celentano, D., et al. (2002). Effect of cocaine use on coronary calcium among black adults in Baltimore, Maryland. Am. J. Cardiol. 90:326–328.

    Article  PubMed  CAS  Google Scholar 

  37. Lai, S., Lai, H., Meng, Q., Tong W., Vlahov, D., and Celentano, D. Coronary Artery Calcium (CAC) scores with PI treatment in HIV+patients. XIV International AIDS Conference; July 7–14, 2002; Barcelona.

  38. Acevedo, M., Sprecher, D.L., Calabrese, L., Pearce, G.L., Coyner, D.L., Halliburton, S.S., et al. (2002). Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: ‘a call for cardiovascular prevention’. Atherosclerosis 163:349–354.

    Article  PubMed  CAS  Google Scholar 

  39. Wanke, C., Lamon-Fava, S., Tang, A., Hendricks, K., Gerrior, J., McNamara, J., et al. Risk factors for CHD and coronary calcification in a cohort of HIV-infected subjects. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 743.

  40. Bozzette, S.A., Ake, C.F., Tam, H.K., Chang, S.W., and Louis, T.A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348:702–710.

    Article  PubMed  CAS  Google Scholar 

  41. Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., and Costagliola, D. (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17:2479–2486.

    Article  PubMed  Google Scholar 

  42. Coplan, P.M., Nikas, A., Japour, A., Cormier, K., Maradit-Kremers, H., Lewis, R., et al. (2003). Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res. Hum. Retroviruses 19:449–455.

    Article  PubMed  CAS  Google Scholar 

  43. Rhew, D.C., Bernal, M., Aguilar, D., Iloeje, U., and Goetz, M.B. (2003). Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin. Infect. Dis. 37:959–972.

    Article  PubMed  CAS  Google Scholar 

  44. Klein, D., Hurley, L.B., and Sidney, S. (2003). Cardiovascular disease and HIV infection. N. Engl. J. Med. 349:1869–1870.

    Article  PubMed  CAS  Google Scholar 

  45. Saves, M., Chene, G., Ducimetiere, P., Leport, C., Le Moal, G., Amoyel, P., et al. (2003). Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin. Infect. Dis. 37:292–298.

    Article  PubMed  Google Scholar 

  46. Vittecoq, D., Escaut, L., Chironi, G., Teicher, E., Monsuez, J.J., Andrejak, M., et al. (2003). Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 17(Suppl. 1):S70-S76.

    PubMed  Google Scholar 

  47. Gardner, L.I., Klein, R.S., Szczech, L.A., Phelps, R.M., Tashima, K., Rompalo, A.M., et al. (2003). Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J. Acquir. Immune Defic. Syndr. 34:320–330.

    Article  PubMed  Google Scholar 

  48. Ashton, C.M., Souchek, J., Petersen, N.J., Menke, T.J., Collins, T.C., Kizer, K.W., et al. (2003). Hospital use and survival among Veterans Affairs beneficiaries. N. Engl. J. Med. 349:1637–1646.

    Article  PubMed  CAS  Google Scholar 

  49. Currier, J.S., Taylor, A., Boyd, F., Dezii, C.M., Kawabata, H., Burtcel, B., et al. (2003). Coronary heart disease in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 33:506–512.

    PubMed  Google Scholar 

  50. Iloeje, U., Yuan, Y., Toomari, A., et al. Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 746.

  51. Moore, R.D., Keruly, J.C., and Lucas, G. Increasing incidence of cardiovascular disease in HIV-infected persons in care. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 132.

  52. Libby, P., Ridker, P.M., and Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105:1135–1143.

    Article  PubMed  CAS  Google Scholar 

  53. Blake, G.J., and Ridker, P.M. (2001). Novel clinical markers of vascular wall inflammation. Circ. Res. 89:763–771.

    PubMed  CAS  Google Scholar 

  54. Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O. III, Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511.

    Article  PubMed  Google Scholar 

  55. Ridker, P.M., Stampfer, M.J., and Rifai, N. (2001). Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485.

    Article  PubMed  CAS  Google Scholar 

  56. Ridker, P.M., Hennekens, C.H., Buring, J.E., and Rifai, N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342:836–843.

    Article  PubMed  CAS  Google Scholar 

  57. Henry, K., Zackin, R., Dube, M., et al. ACTG 5056: C-reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons durably suppressed on an indinavir (IDV)-containing regimen. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 24–28; 2002; Seattle. Abstract 694-T.

  58. Folsom, A.R. (2001). Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb. Haemost. 86:366–373.

    PubMed  CAS  Google Scholar 

  59. Frohlich, J. and Steiner, G. (2000). Dyslipidaemia and coagulation defects of insulin resistance. Int. J. Clin. Pract. Suppl. 113:14–22.

    PubMed  CAS  Google Scholar 

  60. Sobel, B.E. (1996). Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation 93:1613–1615.

    PubMed  CAS  Google Scholar 

  61. Hadigan, C., Meigs, J.B., Rabe, J., D’Agostino, R.B., Wilson, P.W., Lipinska, I., et al. (2001). Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 86:939–943.

    Article  PubMed  CAS  Google Scholar 

  62. Koppel, K., Bratt, G., Schulman, S., Bylund, H., and Sandstrom, E. (2002). Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 29:441–449.

    PubMed  CAS  Google Scholar 

  63. Wolf, K., Tsakiris, D.A., Weber, R., Erb, P., and Battegay, M. (2002). Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J. Infect. Dis. 185:456–462.

    Article  PubMed  CAS  Google Scholar 

  64. Kingsley, L., Smit, E., Riddler, S., et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections: February 4–8, 2001; Chicago. Abstract 538.

  65. Riddler, S.A., Smit, E., Cole, S.R., Li, R., Chmiel, J.S., Dobs, A., et al. (2003). Impact of HIV infection and HAART on serum lipids in men. JAMA 289:2978–2982.

    Article  PubMed  CAS  Google Scholar 

  66. Negredo, E., Ribalta, J., Paredes, R., Ferre, R., Sirera, G., Ruiz, L., et al. (2002). Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16:1383–1389.

    Article  PubMed  CAS  Google Scholar 

  67. Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15:1811–1822.

    Article  PubMed  CAS  Google Scholar 

  68. Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., de la Cruz, J.J., and Gonzalez-Lahoz, J. (2000). Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14:807–812.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, (111) MCL 4C-211 2002 Holcombe Boulevard, 77030, Houston, TX

    Biykem Bozkurt MD

  2. Winters Center For Heart Failure Research, Baylor College of Medicine, Houston, TX

    Biykem Bozkurt MD

Authors
  1. Biykem Bozkurt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Biykem Bozkurt MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bozkurt, B. Cardiovascular toxicity with highly active antiretroviral therapy. Cardiovasc Toxicol 4, 243–260 (2004). https://doi.org/10.1385/CT:4:3:243

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/CT:4:3:243

Key words

Search

Navigation